Stock Market Reviews

Read and share opinions on GILD (Gilead Sciences, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

Latest News

• Why Gilead Sciences (GILD) Dipped More Than Broader Market Today
  Dec 30, 2025
• Gilead (GILD) Reaches Pricing Agreement with US Government to Lower Drug Costs
  Dec 30, 2025
• Is Gilead Sciences (GILD) An Affordable Healthcare Stocks to Invest In?
  Dec 30, 2025
• Update: Gilead Sciences to Acquire Repare Therapeutics' Investigational Cancer Treatment; Repare Shares Rise
  Dec 24, 2025
• Gilead Sciences to Present at Upcoming Investor Conference
  Dec 22, 2025
• Gilead Sciences Exercises Option With Assembly Bio to License Herpes Drugs
  Dec 22, 2025
• Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes
  Dec 22, 2025
• Why Gilead Sciences (GILD) Stock Is Up Today
  Dec 19, 2025
• Gilead and U.S. Government Enter Agreement to Lower Costs of Medicines for Americans
  Dec 19, 2025

GILD News

• Is Gilead Sciences (GILD) An Affordable Healthcare Stocks to Invest In?
  Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best affordable healthcare stocks to buy now. Gilead Sciences, Inc. (NASDAQ:GILD) announced on December 22 that it has exercised its combined option to exclusively license Assembly Bio’s herpes simplex virus (HSV) helicase-primase inhibitor programs, which include long-acting investigational candidates ABI-1179 and ABI-5366 for recurrent genital herpes. Management reported […]
  Dec 30, 2025
• Gilead Sciences to acquire Repare’s RP-3467
  Gilead will pay Repare $25m upfront, and up to an additional $5m upon completion of certain technology transfer activities.
  Dec 26, 2025
• Sector Update: Health Care Stocks Rise Wednesday Afternoon
  Health care stocks were rising in recent early Wednesday afternoon trading, with the NYSE Health Car
  Dec 24, 2025
• Update: Gilead Sciences to Acquire Repare Therapeutics' Investigational Cancer Treatment; Repare Shares Rise
  (Updates with stock move in the headline and last paragraph.) Gilead Sciences (GILD) has signed a
  Dec 24, 2025
• Repare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration
  CAMBRIDGE, Mass. & MONTREAL, December 24, 2025--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced a definitive asset purchase agreement for Gilead Sciences, Inc. to acquire Repare’s polymerase theta (Polθ) ATPase inhibitor, RP-3467 (the "Gilead Agreement").
  Dec 24, 2025
• GILD Exercises Option to License Assembly Bio's Herpes Programs
  Gilead exercises its option to license ASMB's HSV programs for developing long-acting candidates, ABI-1179 & ABI-5366, for recurrent genital herpes.
  Dec 23, 2025
• Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes
  FOSTER CITY, Calif. & SOUTH SAN FRANCISCO, Calif., December 22, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) and Assembly Biosciences, Inc. (Nasdaq: ASMB), today announced Gilead has exercised its combined option to exclusively license Assembly Bio’s herpes simplex virus (HSV) helicase-primase inhibitor programs, including long-acting investigational candidates ABI-1179 and ABI-5366 for recurrent genital herpes. These represent the first programs Gilead will advance under the ongoing Assembly Bio
  Dec 22, 2025
• Gilead Sciences Exercises Option With Assembly Bio to License Herpes Drugs
  Gilead Sciences (GILD) said Monday that it has exercised its option to exclusively license Assembly
  Dec 22, 2025
• Gilead Sciences to Present at Upcoming Investor Conference
  FOSTER CITY, Calif., December 22, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conference:
  Dec 22, 2025
• Dow Jones Futures Rise; Palantir, GE Lead 12 Stocks In Buy Zones
  Bearish conditions on Wednesday turned bullish by Friday's close, with the S&P 500 and Nasdaq back above their 50-day lines. Palantir and GE lead a slew of new buys.
  Dec 22, 2025
• Faron Announces Strategic Collaboration with The Institute for Cancer Research to Launch BLAZE Trial, Targeting Immunotherapy Resistance in Cancer
  Investigator-initiated trial aims to provide proof-of-concept for bexmarilimab in overcoming acquired resistance to checkpoint inhibitors, a major challenge for most melanoma and lung cancer patients TURKU, FI / ACCESS Newswire / December 22, 2025 ...
  Dec 22, 2025
• Dow Jones Futures: Bulls In Charge; Palantir, GE Lead 12 Stocks In Buy Zones
  Bearish conditions on Wednesday turned bullish by Friday's close, with the S&P 500 and Nasdaq back above their 50-day lines. Palantir and GE lead a slew of new buys.
  Dec 20, 2025
• Dow Jones Futures: Bearish To Bullish In Two Days; Palantir, GE Lead 12 Stocks In Buy Zones
  Bearish conditions on Wednesday turned bullish by Friday's close, with the S&P 500 and Nasdaq back above their 50-day lines. Palantir and GE lead a slew of new buys.
  Dec 20, 2025
• Trump reaches deal with 9 drug companies to lower prices
  President Trump announced deals with nine major drug makers in a move to reduce pharmaceutical prices, granting a three-year break on trade tariffs if they invest more into US manufacturing. Market Domination Overtime host Jared Blikre breaks down the news. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime.
  Dec 19, 2025
• Sector Update: Health Care Stocks Rise Late Afternoon
  Health care stocks rose late Friday afternoon, with the NYSE Health Care Index increasing 0.8% and t
  Dec 19, 2025
• Why Gilead Sciences (GILD) Stock Is Up Today
  Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) jumped 3.3% in the afternoon session after the stock's positive momentum continued as the company announced a series of positive developments, including successful late-stage trial results for a new HIV treatment, regulatory approval for another HIV drug in the U.K., and a new pricing agreement with the U.S. government.
  Dec 19, 2025
• Top Midday Stories: Oracle, Others Form JV to Oversee TikTok in US; More Drugmakers to Announce US Drug Price Deals
  All three major US stock indexes were up in late-morning trading Friday, as the artificial-intellige
  Dec 19, 2025
• Nine Drugmakers Strike Deals With Trump, With More to Come
  The most recent pledges mean 14 of the 17 drugmakers targeted by Trump this summer have agreed to lower prices for the Medicaid program for low-income and disabled people, sell discounted drugs directly to consumers and launch new medicines for the same prices in the US as they do abroad. “American drug prices will come down fast and furious, and will soon be among the lowest in the developed world,” Trump said during an event in the Oval Office.
  Dec 19, 2025
• Gilead and U.S. Government Enter Agreement to Lower Costs of Medicines for Americans
  FOSTER CITY, Calif., December 19, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced an agreement with the U.S. government designed to reduce drug costs for Americans, reinforcing the company’s long-standing commitment to U.S.-based innovation, affordability, and global health leadership.
  Dec 19, 2025
• Nine Big Drugmakers Reach Pricing Deals With White House
  Nine pharmaceutical companies including Merck and GSK agreed to lower certain U.S. prices for their medicines in a new round of industry pacts with the Trump administration. The companies agreed to reduce U.S. prices on drugs to levels comparable with prices charged in other wealthy countries, which are generally much lower. Merck, for example, said it would make diabetes drugs Januvia and Janumet available to eligible American patients at a cash price that is 70% off the current list price through a direct-to-patient program.
  Dec 19, 2025
• Dow Jones' Merck, Other Drugmakers Strike Drug-Pricing Bargains With Trump
  Dow Jones stock Merck and eight other bellwether pharma companies struck drug-pricing agreements with the Trump administration on Friday.
  Dec 19, 2025
• Does Gilead Still Offer Value After Its 2025 Surge and Pipeline Progress?
  Wondering if Gilead Sciences is still a smart buy after its big run, or if the stock has already priced in the good news? Here is a breakdown of whether the current share price really lines up with the underlying value. Gilead is flat over the last week and down 2.2% over the past month, but the stock is still up 32.1% year to date and 37.6% over the last year, with gains of 58.2% in 3 years and 156.3% in 5 years. Behind these moves, investors have been reacting to a steady stream of...
  Dec 18, 2025
• Gilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance
  FOSTER CITY, Calif., December 18, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Keeley Wettan will be appointed Executive Vice President, General Counsel, Legal & Compliance effective immediately. She will join the company’s senior leadership team and report to Chairman and Chief Executive Officer Daniel O’Day.
  Dec 18, 2025
• Gilead Sciences (GILD) Valuation After Positive Phase 3 Data for Its Bictegravir–Lenacapavir HIV Regimen
  Gilead Sciences (GILD) just cleared an important milestone: its once daily bictegravir and lenacapavir combo matched Biktarvy in the Phase 3 ARTISTRY 2 trial, with clean safety data that strengthens the longer term HIV pipeline story. See our latest analysis for Gilead Sciences. The stock has cooled a little in the last month, with a 30 day share price return of minus 4.6 percent. That still sits within a strong 32.1 percent year to date share price gain and a 5 year total shareholder return...
  Dec 18, 2025
• Gilead Sciences (GILD) Increases Despite Market Slip: Here's What You Need to Know
  Gilead Sciences (GILD) closed the most recent trading day at $121.36, moving +2.17% from the previous trading session.
  Dec 17, 2025
• GILD's Bictegravir and Lenacapavir Regimen for HIV Meets Primary Goal
  Gilead said its once-daily bictegravir/lenacapavir tablet met non-inferiority vs Biktarvy in phase III ARTISTRY-2, paving the way for filings.
  Dec 16, 2025
• FDA ‘proactively’ hands J&J a voucher; Pfizer issues 2026 forecasts
  The FDA contacted J&J right after ASH to discuss using a special fast pass on a multiple myeloma regimen. Elsewhere, a new cell therapy player emerged with $60 million in Series A funding.
  Dec 16, 2025
• RCUS Stock Down on Decision to Discontinue GILD Partnered Study
  Arcus halts the late-stage STAR-221 study for futility, dealing a setback to its domvanalimab program with Gilead. Stock down.
  Dec 15, 2025
• Alger Russell Innovation Index Updates for Fourth Quarter 2025
  Fred Alger Management, LLC ("Alger"), a privately held growth equity investment manager, today announced the quarterly rebalancing of the Alger Russell Innovation Index ("Index"). Following the close of trading on Friday, December 19, 2025, the Index will be rebalanced, and the following changes will be effective.
  Dec 15, 2025
• Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial
  FOSTER CITY, Calif., December 15, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ARTISTRY-2 trial. The double-blind trial evaluated the treatment responses of adults with HIV who are virologically suppressed switching from BIKTARVY® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) to a fixed-dose combination of bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN). BIC/LEN efficacy was found to be statistically no
  Dec 15, 2025
• 3 Companies Turning Big Cash Flow Into Bigger Shareholder Gains
  GILD, AMAT, and QCOM all stand out for their capacity to generate cash flow, which allows them to increase value to shareholders through dividends and buybacks.
  Dec 15, 2025
• Is Earlier Yescarta Use in Lymphoma Altering The Investment Case For Gilead Sciences (GILD)?
  Kite, a Gilead Sciences company, recently reported new analysis showing that its CAR T therapy Yescarta delivers consistent benefits as a second-line treatment for patients with relapsed or refractory large B-cell lymphoma, including those previously considered ineligible for standard high-dose chemotherapy and stem cell transplant. This finding could encourage oncologists to use Yescarta earlier in the treatment pathway, potentially strengthening Gilead’s position in the fast-growing cell...
  Dec 13, 2025
• Kymera's Eczema Drug Gets Fast Track Designation in the United States
  KYMR gains momentum as the FDA grants Fast Track to KT-621 for moderate to severe atopic dermatitis, boosting the stock and advancing its Type 2 pipeline.
  Dec 12, 2025
• Arcus cancels work on Gilead-partnered cancer combo after trial setback
  A study using TIGIT and PD-1 drugs for gastrointestinal disease was canceled for “futility” at an early checkpoint, another blow to research on a once-promising target.
  Dec 12, 2025
• Why Arcus Biosciences Just Reversed Its 287% Eight-Month Winning Streak
  Arcus Biosciences stock plunged Friday, reversing a nearly 300% gain, after its Gilead Sciences-partnered cancer regimen failed.
  Dec 12, 2025
• 3 Profitable Stocks We Keep Off Our Radar
  While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".
  Dec 11, 2025
• Arcellx, Inc. (ACLX) Makes Progress on Multiple Myeloma Treatment
  Arcellx Inc. (NASDAQ:ACLX) is one of the best biotech stocks to buy according to Wall Street analysts. On December 8, the company delivered promising Pivotal Phase 2 study results of anitocabtagene autoleucel (anito-cel) in patients with relapsed or refractory multiple myeloma. The company is developing an anti-CD in partnership with Kite, a Gilead company unit, […]
  Dec 11, 2025
• Leading Multiple Myeloma Results Unveiled at ASH 2025: Paradigm-Shifting Data Redefines Treatment Landscape | DelveInsight
  The 67th American Society of Hematology (ASH) Annual Meeting, held December 6-9, 2025, in Orlando, Florida, showcased groundbreaking clinical advances in multiple myeloma treatment from leading biopharmaceutical companies. The conference featured unprecedented efficacy data demonstrating potential functional cures and innovative approaches across novel immunotherapies, bispecific antibodies, and next-generation targeted agents, signaling a major shift in how the disease is managed.
  Dec 11, 2025
• Here's What We Like About Gilead Sciences' (NASDAQ:GILD) Upcoming Dividend
  Gilead Sciences, Inc. ( NASDAQ:GILD ) stock is about to trade ex-dividend in 4 days. The ex-dividend date is one...
  Dec 10, 2025
• Cantor Fitzgerald Maintains a Buy Rating on Gilead Sciences (GILD)
  Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best pharma stocks to invest in. Cantor Fitzgerald analyst Carter Gould maintained a Buy rating on Gilead Sciences, Inc. (NASDAQ:GILD) on December 7, setting a price target of $135. The same day, Kite, a Gilead Sciences, Inc. (NASDAQ:GILD) company, released a new analysis showing that second-line Yescarta therapy […]
  Dec 10, 2025
• New Study: Integrative Therapy and Nurse Navigation Reduce Treatment Side Effects for 75% of Black Breast Cancer Patients; 85% Report Lower Distress
  ANNAPOLIS, Md. & PHILADELPHIA, December 10, 2025--Leading breast cancer nonprofits Unite for HER and TOUCH, The Black Breast Cancer Alliance (TOUCHBBCA) presented new and critical research addressing health disparities, entitled "A New Comprehensive Integrative Care and Navigation Model for Enhancing Outcomes for Black Breast Cancer Patients: Evidence from the Care for HER Program​" at the 2025 San Antonio Breast Cancer Symposium.
  Dec 10, 2025
• Gilead Foundation Awards Over $3 Million to Support People Living With Metastatic Breast Cancer
  FOSTER CITY, Calif., December 09, 2025--Gilead Foundation awards $3M in grants to close gaps in education, care, and support for people living with metastatic breast cancer.
  Dec 9, 2025
• Mirum to buy Bluejay for up to $820m in rare liver disease push
  The deal gives Mirum access to Bluejay’s monoclonal antibody brelovitug, which is currently in Phase III trials.
  Dec 9, 2025
• Why The Narrative Around Gilead Sciences Is Shifting After HIV And Oncology Updates
  Gilead Sciences stock has seen its fair value estimate edge down only slightly, from about $130.83 to $130.63, even as the discount rate nudged up from roughly 7.26% to 7.29% and long term revenue growth expectations eased from around 3.89% to 3.68%. These modest adjustments reflect analysts fine tuning their models in light of a more nuanced mix of tailwinds, such as extended HIV cash flows and a larger PrEP opportunity, and headwinds, such as execution risk in next generation programs and...
  Dec 7, 2025
• Yescarta® Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025
  SANTA MONICA, Calif., December 07, 2025--Kite, a Gilead Company (Nasdaq: GILD), presented a new analysis today demonstrating that second-line Yescarta® (axicabtagene ciloleucel) therapy offers consistent benefits in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL), even among those ineligible for the previous standard of care, high-dose chemotherapy followed by an autologous stem cell transplant (ASCT).
  Dec 7, 2025
• Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel’s Opportunity in Relapsed or Refractory Multiple Myeloma
  SANTA MONICA, Calif., December 06, 2025--Kite, a Gilead Company (Nasdaq: GILD), and its partner Arcellx, today announced new positive data from its pivotal iMMagine-1 Phase 2 study of anitocabtagene autoleucel (anito-cel), an investigational agent, which continues to show clinically meaningful deep and durable efficacy with predictable and manageable safety observed to date in relapsed or refractory multiple myeloma (RRMM) patients who had received at least three prior lines of therapy. These ne
  Dec 6, 2025
• Kite’s Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025
  SANTA MONICA, Calif., December 06, 2025--Kite, a Gilead Company (Nasdaq: GILD), presented Phase 1 data today with encouraging efficacy and safety results for its two investigational bicistronic CAR T-cell therapies, KITE-753 and KITE-363, respectively, in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL). The results of the analysis were shared in an oral presentation (Abstract #265) at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition.
  Dec 6, 2025
• 3 Unpopular Stocks We Think Twice About
  Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.
  Dec 4, 2025
• Gilead (GILD) Valuation After Fresh Buy Rating and Extended Biktarvy Exclusivity Boost Investor Confidence
  Gilead Sciences (GILD) just got a confidence boost from Wall Street, with Truist initiating coverage at Buy and Mizuho flagging a longer US exclusivity window for HIV flagship Biktarvy after key litigation settlements. See our latest analysis for Gilead Sciences. The mix of upbeat HIV and oncology commentary and a longer Biktarvy exclusivity window has helped support sentiment, with a roughly 36 percent year to date share price return and a 5 year total shareholder return above 150 percent...
  Dec 4, 2025
• Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
  Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
  Dec 4, 2025
• Axsome (AXSM) Up 5.3% Since Last Earnings Report: Can It Continue?
  Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
  Dec 3, 2025
• Is Vera Therapeutics (VERA) Quietly Recasting Its Commercial Strategy With the Meyers Board Appointment?
  Vera Therapeutics recently appointed James R. Meyers, a biopharmaceutical executive with more than three decades of commercial leadership at companies including Gilead and AstraZeneca, to its Board of Directors. Meyers’ track record in leading global launches in HIV and HCV and guiding Gilead’s evolution into a large, profitable biopharma adds weight to Vera’s commercial ambitions as it advances its pipeline. We’ll now examine how adding Meyers’ extensive commercial expertise to the board...
  Dec 3, 2025
• National AIDS Memorial Marks World AIDS Day with Two Signature Events Highlighting the Power of Communities to Shape Progress in the Fight Against HIV/AIDS and Advance Health and Social Justice
  SAN FRANCISCO, December 01, 2025--The National AIDS Memorial commemorated World AIDS Day with two powerful, community-centered events at the National AIDS Memorial Grove ("the Grove") in San Francisco. Having entered its 35th anniversary year in September 2025, the Grove has long served as a gathering place for remembrance and inspiration, reflecting the overarching theme of this year’s events: Community Driving Change. Gilead Sciences served as the Presenting Partner of both events.
  Dec 1, 2025
• 5 Healthcare Names to Watch as Sector Rotation Is in Full Swing
  The healthcare sector is outperforming the broader market and tech sector in Q4, confirming a substantial capital shift into the defensive industry.
  Dec 1, 2025
• Gilead (GILD) Earns Buy Rating at Truist as HIV Franchise Continues to Deliver
  Gilead Sciences, Inc. (NASDAQ:GILD) is included among the 15 Best Boring Dividend Stocks to Buy. On Novemb‍er 24, Truist’​s‍ Gregor‌y Ren⁠za in​itiated coverage of Gilead Sciences, Inc. (NASDAQ:GILD) with a Buy rating and se​t a price target of $14‌0, s‌lightly below th‌e pre​vi‌ous $1⁠45, as reported by The Fly. In‍ his note to investors,⁠ he […]
  Nov 30, 2025
• Gilead Sciences (GILD) Stock Outlook: Mizuho Lifts Target Amid Stronger Biktarvy Timeline
  Gilead Sciences, Inc. (NASDAQ:GILD) ranks among the best slow growth stocks to invest in. On November 21, Mizuho increased its price target for Gilead Sciences, Inc. (NASDAQ:GILD) from $131 to $140 while maintaining the stock’s Outperform rating. The firm cited a number of factors for the adjustment, including a longer exclusivity period for Biktarvy, with […]
  Nov 29, 2025
• Will Expanding Lenacapavir Access in Africa Reshape Gilead Sciences' (GILD) Global Healthcare Narrative?
  Earlier this month, Gilead Sciences announced the first shipments of its twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, for HIV prevention to Eswatini and Zambia, marking a significant step in global access initiatives for this therapy. This move highlights Gilead’s ability to rapidly bring innovative HIV prevention to regions with high disease burden, fostering global health partnerships and expanding its reach in emerging markets. We'll now explore how Gilead's expanded...
  Nov 29, 2025
• Bristol Myers vs Gilead Sciences: Which Biotech Stock Is a Better Bet Now?
  GILD's HIV strength, new approvals, and rising estimates set it apart as it edges past a challenged rival in growth prospects.
  Nov 28, 2025
• Is Gilead Sciences a Bargain After 40% Share Price Surge and Pipeline Updates?
  Ever wondered if Gilead Sciences might be trading for less than it's worth? Let’s dig into its recent moves to see if there's a value opportunity hiding in plain sight. Gilead Sciences' stock has been on the rise, climbing 6.2% over the past month and surging 37.0% year-to-date, for a strong 40.0% jump over the last year. Healthcare headlines have been buzzing, with recent positive developments around Gilead’s pipeline treatments and strategic partnerships attracting fresh attention from...
  Nov 28, 2025
• Kymera Trades Near 52-Week High: Time to Buy, Sell or Hold the Stock?
  KYMR hits a 52-week high as optimism builds around KT-621's progress and upcoming data in atopic dermatitis.
  Nov 26, 2025
• Gilead scoops up a preclinical cancer program
  The company, which invested heavily in oncology in recent years, has now put more than $400 million on the table to access a Sprint Bioscience drug targeting “TREX1.”
  Nov 25, 2025
• Is Gilead Sciences Stock Outperforming the Dow?
  Gilead Sciences has outperformed the Dow Jones over the past year, and analysts are upbeat about the healthcare stock's prospects.
  Nov 25, 2025
• Gilead snaps up Sprint’s TREX1 immunotherapy programme for $400m
  Gilead’s new immunotherapy asset targets the TREX1 protein, which is a novel target in oncology.
  Nov 25, 2025
• Gilead Foundation Commits Over $3 Million to Address Food Insecurity
  FOSTER CITY, Calif., November 24, 2025--Gilead Foundation today announced that it has committed over $3 million in grants to expand access to food in communities across the United States. Gilead Foundation Healing Hunger awards will enable 14 regionally focused organizations to meet the unique needs of their communities by improving long-term nutrition access. The funding, distributed through the Gilead Foundation, supports organizations addressing food insecurity in California, North Carolina,
  Nov 24, 2025
• Investors bet on newer technology and indications for CGTs
  The industry is showing enthusiasm for novel technologies that improve safety and carry innovation potential including in vivo CAR-Ts.
  Nov 24, 2025
• MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC
  Merck reports strong new HIV study results showing non-inferiority of DOR/ISL to Gilead's Biktarvy and secures an EU approval for its faster-to-administer SC version of Keytruda.
  Nov 20, 2025
• Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock
  Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
  Nov 20, 2025
• Gilead Sciences (GILD): Taking Stock of Valuation as Shares Approach Analyst Targets
  Gilead Sciences (GILD) stock has drawn the attention of investors with its recent performance over the past month, gaining about 4%. With steady annual revenue and net income growth, there is renewed interest in how the company is positioned within the sector. See our latest analysis for Gilead Sciences. Gilead Sciences has enjoyed a wave of positive momentum lately, with its latest share price of $128.07 reflecting strong interest. The company’s share price return year-to-date stands at...
  Nov 20, 2025
• Aspen Neuroscience Announces $115 Million Series C Financing to Accelerate Personalized Cell Therapy Programs
  Aspen Neuroscience, Inc., a clinical-stage biotechnology company pioneering autologous regenerative therapies, today announced the closing of a $115 million Series C financing round. This significant investment will fuel the continued clinical development of Aspen's lead program, ANPD001, for moderate to advanced Parkinson's disease.
  Nov 20, 2025
• Liver Failure Market Analysis Report 2025-2035: Gilead Sciences, AbbVie, and Boehringer Ingelheim Lead Advancements in Liver Failure Treatments and Artificial Liver Support Technologies
  Liver failure is a critical condition where the liver loses its ability to detoxify, synthesize proteins, and regulate biochemical processes. It can result from hepatitis, alcohol abuse, NAFLD, autoimmune diseases, or toxins. Key symptoms include jaundice, encephalopathy, ascites, and bleeding. The global liver failure market is expanding due to rising disease prevalence, enhanced healthcare access, and diversified therapies. Innovations in transplantation, artificial liver systems, and pharmaco
  Nov 19, 2025
• Portal Hypertension Drugs Market Research Report 2025-2035: Key Dynamics, Pipeline Analysis, Regulatory Landscape, Epidemiology
  The global portal hypertension drugs market is thriving due to rising liver disease rates, particularly cirrhosis and hepatitis, and an aging global population, leading to heightened demand for effective therapies. Key players like Gilead Sciences and Novartis are driving market growth through innovation and strategic partnerships. Despite challenges such as high treatment costs and limited access, ongoing R&D aims to introduce affordable solutions. As awareness of liver health expands, technolo
  Nov 19, 2025
• Healthcare’s Momentum Gathers Steam. 3 Stocks With Bullish Charts.
  FEATURE Healthcare stocks are recovering strongly as the year winds down. The is the best-performing of 11 major S&P sector funds over the past week, month, and three-month periods. The appeal of this group is its variety.
  Nov 19, 2025
• Gilead Joins Partners for Delivery of First Shipments of Breakthrough Twice-yearly Lenacapavir for HIV Prevention to Sub-Saharan Africa
  FOSTER CITY, Calif. & MBABANE, Eswatini, November 18, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the delivery of first shipments of lenacapavir – Gilead’s twice-yearly injectable HIV-1 capsid inhibitor – for the prevention of HIV as pre-exposure prophylaxis (PrEP) to Eswatini and Zambia. The deliveries advance ongoing efforts to accelerate equitable access to long-acting HIV prevention options across sub-Saharan Africa, which is home to approximately two-thirds of all people livi
  Nov 18, 2025
• Eli Lilly Upgraded, Chewy Downgraded: Updated Rankings on Top Blue-Chip Stocks
  During these busy times, it pays to stay on top of the latest profit opportunities. And today’s blog post should be a great place to start. After taking a close look at the latest data on institutional buying pressure and each company’s fundamental health, I decided to revise my Stock Grader recommendations for 141 big blue chips. Chances are that you have at least one of these stocks in your portfolio, so you may want to give this list a skim and act accordingly. This Week’s Ratings Changes: Up
  Nov 17, 2025
• Scotiabank Analyst Sees Opportunity in Large Cap Biopharma, Keeps Outperform on GILD
  Gilead Sciences, Inc. (NASDAQ:GILD) is included among the 15 Best Passive Income Stocks to Buy Right Now. On November 12, Scotiabank an⁠aly​st Louise Chen began coverage on ten large-cap biopharma companies an⁠d sh​ared‍ an “‍o‌ut-of-c⁠onsensus” positive view o‌n the‍ sector, according to a report by The Fly. She pointed out that years of underperfor‍manc‌e in […]
  Nov 16, 2025
• Gilead Sciences, Inc. (GILD)’s Mixed Quarter Draws Divergent Analyst Views
  Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best blue-chip stocks to buy now. On November 3, Bernstein SocGen Group reiterated its “Outperform” rating on Gilead Sciences, Inc. (NASDAQ: GILD), setting a price target of $135. The firm highlighted the company’s solid third-quarter performance and noted continued strength in HIV therapies and emerging treatments as […]
  Nov 15, 2025
• Is Gilead’s Successful Phase 3 HIV Regimen Trial Shifting the Investment Case for GILD?
  Gilead Sciences recently announced that its Phase 3 ARTISTRY-1 trial met the primary endpoint for a novel single-tablet HIV regimen combining bictegravir and lenacapavir, confirming non-inferiority versus multi-tablet therapy and reporting a favorable safety profile. This development highlights Gilead’s continued progress in simplifying treatment for people living with HIV and advancing next-generation regimens that address patient needs for convenience and tolerability. We’ll examine how...
  Nov 14, 2025
• 1 Healthcare Stock to Own for Decades and 2 We Avoid
  Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, limiting growth. This has capped returns as the industry’s six-month gain of 11.6% has lagged the S&P 500’s 16.3% climb.
  Nov 14, 2025
• GILD's Investigational Regimen for HIV Treatment Meets Primary Goal
  Gilead's ARTISTRY-1 success boosts shares as its once-daily bictegravir/lenacapavir combo proves non-inferior to complex regimens.
  Nov 14, 2025
• Lundbeck sparks bidding war with Alkermes; Pfizer closes Metsera deal
  Pfizer quickly consummated the $10 billion buyout after one-upping Novo Nordisk. Elsewhere, Lundbeck submitted a rival offer for Avadel Pharmaceuticals and Zealand Pharma dropped an obesity drug.
  Nov 14, 2025
• Assessing Gilead After 34% Rally and Recent Pharmaceutical Partnerships
  Curious whether Gilead Sciences is a hidden gem or if the current stock price already reflects all its upside? Let’s break down the numbers and see if there's value yet to be uncovered. After a strong year with a 37.2% gain and an impressive 34.3% jump year to date, the market’s perception of Gilead’s risk and growth potential appears to be evolving. Recent headlines highlight the company’s steady stream of new treatment approvals and strategic partnerships, both of which have bolstered...
  Nov 13, 2025
• Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls
  Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls
  Nov 13, 2025
• 2 Supercharged Dividend Stocks to Buy Now
  Innovative drugmakers often make for solid dividend stocks. These two companies are great examples.
  Nov 13, 2025
• Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-1 Trial
  FOSTER CITY, Calif., November 13, 2025--Gilead Sciences, Inc. (NASDAQ: GILD) today announced positive topline results from the Phase 3 ARTISTRY-1 trial. The open-label trial evaluated the treatment responses of adults with HIV who are virologically suppressed switching from a multi-tablet regimen to an investigational single-tablet regimen of bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN). BIC/LEN efficacy was found to be statistically non-inferior to multi-tablet regimens. Gilead plans to file t
  Nov 13, 2025
• Here Are Thursday’s Top Wall Street Analyst Research Calls: AbbVie, AppLovin, Autozone, Booking Holdings, CoreWeave, DoorDash, and More
  Pre-Market Stock Futures: The stock futures are trading lower on Thursday, following another incredible day for the Dow Jones Industrials, while the rotation out of the NASDAQ and into technology is still gaining traction. The DJIA posted a record all-time high, closing at 48,254, up another 327 points or 0.68%. The S&P 500 just barely ... Here Are Thursday’s Top Wall Street Analyst Research Calls: AbbVie, AppLovin, Autozone, Booking Holdings, CoreWeave, DoorDash, and More
  Nov 13, 2025
• Compugen Ltd (CGEN) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
  Compugen Ltd (CGEN) showcases promising drug discovery initiatives and strategic partnerships, despite facing revenue declines and trial delays.
  Nov 12, 2025
• MacroGenics Reports Third Quarter 2025 Financial Results and Provides Update on Corporate Progress
  Achieved additional $75 million in partnering proceeds from Sanofi and GileadGranted license to additional preclinical program to Gilead that leverages MacroGenics’ novel T-cell engager platformRealigned pipeline priorities by ending development of lorigerlimab in prostate cancer while continuing development in ovarian cancerCash runway guidance extended into late 2027 ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on devel
  Nov 12, 2025
• Gilead Sciences, Moderna, Artivion, Tenet Healthcare, and Charles River Laboratories Stocks Trade Up, What You Need To Know
  A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns. This divergence was stark: the tech-heavy Nasdaq struggled, losing 0.2%, while the Dow rallied. This shift away from tech was triggered by a series of negative catalysts in the AI sector. AI cloud provider CoreWeave slid on disappointing guidance, while chip darling Nvidia
  Nov 11, 2025
• Pulmonary Arterial Hypertension Market Research Report 2025, Competitive Analysis of Gilead Sciences, Viatris, Sandoz, J&J, Sun Pharma, Lupin Pharma, GlaxoSmithKline, Bayer, United Therapeutics
  Market opportunities in the Pulmonary Arterial Hypertension (PAH) sector include increased demand for innovative therapies due to rising PAH prevalence and greater awareness, alongside enhanced diagnostic capabilities. The shift towards personalized medicine and digital health tools also offers avenues for optimizing treatment efficacy and patient management. Pulmonary Arterial Hypertension Market Pulmonary Arterial Hypertension Market Dublin, Nov. 11, 2025 (GLOBE NEWSWIRE) -- The "Pulmonary Art
  Nov 11, 2025
• AHF’s Mobile Billboard Calls Out Gilead’s Greed at Pharma Summit
  LOS ANGELES, November 10, 2025--As the pharmaceutical industry gathers for the Global Pharma & Biotech Summit in London this week, AIDS Healthcare Foundation (AHF) is launching a mobile billboard that will circle the venue (Convene 22 Bishopsgate) on Nov. 11-12 to spotlight Gilead Sciences’ greed and refusal to make its breakthrough HIV prevention drug lenacapavir truly affordable and accessible.
  Nov 10, 2025
• Compugen Reports Third Quarter 2025 Results
  Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational target discovery powered by AI/ML, today reported financial results for the third quarter of 2025 and provided a corporate update.
  Nov 10, 2025
• How Recent Developments Are Shaping the Gilead Sciences Investment Story
  Recent analyst updates have led to a slight increase in Gilead Sciences’ fair value price target, moving from $127.23 to $129.51. This change is supported by renewed confidence in the company’s performance and potential, along with a minor uptick in perceived investment risk. Stay tuned to see how you can keep up with evolving perspectives in this dynamic narrative. Stay updated as the Fair Value for Gilead Sciences shifts by adding it to your watchlist or portfolio. Alternatively, explore...
  Nov 8, 2025
• Sector Update: Health Care Stocks Ease Late Afternoon
  Health care stocks edged lower late Friday afternoon, with the NYSE Health Care Index shedding 0.1%
  Nov 7, 2025
• Sector Update: Health Care Stocks Retreat Friday Afternoon
  Health care stocks declined Friday afternoon, with the NYSE Health Care Index and the Health Care Se
  Nov 7, 2025

GILD Reviews

• MoneyMage

  Dec 30, 2025

  $GILD Big promises but falling short of expectations.

  Sell

• TheLongPlay

  Dec 29, 2025

  $GILD Medicinal magic on the rise, they’re makin' moves!

  Buy

• RiskRanger

  Dec 27, 2025

  $GILD They’re like a superhero for your health, swooping in to save the day – capes not included!

  Buy

• AlphaRift

  Dec 27, 2025

  $GILD This organization is known for its robust pipeline of therapeutics, making significant advancements in treatment options for chronic diseases. Their ongoing research and development efforts position them as a leader in the biotech field.

  Buy

• TradeProtocol

  Dec 26, 2025

  $GILD If science were a superhero, this crew would be wearing capes and saving the world, one molecule at a time!

  Buy

• TrendHunter

  Dec 26, 2025

  $GILD This one's getting old fast; it needs some life support.

  Sell

• TrendScript

  Dec 25, 2025

  $GILD Renowned for its contributions to the biopharmaceutical industry, this company continues to innovate in areas that have a significant impact on global health. Its pipeline and research initiatives promise to keep it at the forefront of the market.

  Buy

• BagholderElite

  Dec 24, 2025

  $GILD Solid player in the ring, making moves like a champ.

  Buy

• AlphaRogue

  Dec 24, 2025

  $GILD This bio-pharma giant is like a magician—making problems disappear with their potions and cures. Abracadabra, health!

  Buy

• OptionCipher

  Dec 22, 2025

  $GILD The weight of expectations is heavy on this company as it faces critical trials ahead. Will they rise to the occasion, or crumble under the pressure?

  Sell

• Stonks4Days

  Dec 22, 2025

  $GILD Old school but still packing a punch, respect that hustle!

  Sell

• BagholderPrime

  Dec 20, 2025

  $GILD Imagine a superhero in a lab coat fighting off diseases! This company is ready to save the day, one pill at a time.

  Buy

• WallStreetGrim

  Dec 19, 2025

  $GILD With its strong commitment to research and development, this industry giant continues to advance healthcare solutions that address critical unmet needs.

  Buy

• AlphaWave

  Dec 18, 2025

  $GILD As the clock ticks, the healthcare market is as competitive as ever. Innovations are vital, but will they come in time to change the game?

  Sell

• EquityPulse

  Dec 18, 2025

  $GILD With developments on the horizon, the stakes are high! Will they deliver the groundbreaking results everyone is anticipating? It's a real cliffhanger!

  Buy

• ShortSniper

  Dec 18, 2025

  $GILD They’re stuck in a rut, waiting for a miracle that won’t come.

  Sell

• FiscalFrost

  Dec 17, 2025

  $GILD Renowned for its contributions to healthcare, this firm is navigating a complex landscape with a strong pipeline of products. Its robust research initiatives reflect a commitment to innovation, which may enhance long-term value.

  Buy

• CandleCrusher

  Dec 15, 2025

  $GILD The relentless push for breakthroughs in health leaves this company at the edge of innovation, but the pressure is mounting, and recent results have many investors on the edge of their seats. Can they deliver when it counts the most?

  Sell

• YieldVector

  Dec 15, 2025

  $GILD With all the news swirling around, this one’s got the spotlight! The pressure's on—watch out for sudden shifts that could catch you off guard.

  Sell

• DividendDegen

  Dec 15, 2025

  $GILD Big player in the health scene, keep your eyes peeled for big moves!

  Sell

• RiskVandal

  Dec 14, 2025

  $GILD Once a giant, now just a shadow of its former glory.

  Sell

• TickerTakedown

  Dec 14, 2025

  $GILD This company works on curing diseases, not just making money. Kind of like bringing cookies to a bake sale, but with higher stakes!

  Buy

• GainSurge

  Dec 13, 2025

  $GILD In the race against time for breakthroughs, can this giant maintain its edge or will new players steal the spotlight? The clock is ticking and tensions are high!

  Sell

• StonkPhantom

  Dec 13, 2025

  $GILD Corrections are shallow — strong sign.

  Buy

• TradeReckoner

  Dec 12, 2025

  $GILD Once a powerhouse, now just a shadow of its former self.

  Sell

• EarningsSync

  Dec 12, 2025

  $GILD Distribution showing on volume profile.

  Sell

• HODLzilla

  Dec 12, 2025

  $GILD Momentum turning sharply upward.

  Buy

• YieldSlasher

  Dec 12, 2025

  $GILD A giant that’s lost its magic touch.

  Sell

• PortfolioFreak

  Dec 11, 2025

  $GILD Investors are feeling the heat as this company navigates tough market dynamics. With ambitious targets and intense scrutiny, can it deliver results without succumbing to the stress? The atmosphere is charged.

  Sell

• RiskRanger

  Dec 11, 2025

  $GILD When your science game is so strong, even your lab coat has its own fan club! Talk about chemistry!

  Buy

• HoldTheLine

  Dec 11, 2025

  $GILD They’re on fire with killer treatments, can’t stop, won’t stop!

  Buy

• AlphaRift

  Dec 11, 2025

  $GILD Renowned for its groundbreaking contributions to medicine, this firm continues to push boundaries in research and development. Their strong pipeline of potential treatments underscores a commitment to addressing global health challenges.

  Buy

• TradingNomad

  Dec 11, 2025

  $GILD The constant news surrounding this biotech giant keeps everyone on edge. They have the potential for life-changing treatments, but will they deliver on the hype? The clock is ticking!

  Buy

• PortfolioGremlin

  Dec 11, 2025

  $GILD Strong buying tail observed.

  Buy

• MemeInvestor

  Dec 11, 2025

  $GILD Bearish continuation nearly confirmed.

  Sell

• TradingNomad

  Dec 11, 2025

  $GILD Clear path to upside resistance.

  Buy

• OptionOverlord

  Dec 11, 2025

  $GILD Bearish price rejection confirmed.

  Sell

• YieldVector

  Dec 11, 2025

  $GILD Too many red flags in chart.

  Sell

• DividendDegen

  Dec 11, 2025

  $GILD Holding strong, but watch out for the competition lurking.

  Sell

• DividendHunter

  Dec 11, 2025

  $GILD Once a giant, now just a nostalgic memory.

  Sell

• CandleCrusher

  Dec 11, 2025

  $GILD With countless challenges in pharmaceuticals, competition is fierce and the clock is ticking. Will they rise to the occasion or get left behind?

  Buy

• BullRunBandit

  Dec 10, 2025

  $GILD Rock solid in health, this one's still got the juice!

  Buy

• ShortSavior

  Dec 10, 2025

  $GILD Once a star, now just dimmed expectations.

  Sell

• AlphaRift

  Dec 9, 2025

  $GILD The organization is recognized for its significant contributions to healthcare, particularly in developing treatments that address critical medical needs. Their robust pipeline indicates a commitment to ongoing innovation and patient care.

  Buy

• AlphaWave

  Dec 9, 2025

  $GILD In the high-stakes biopharma world, can this company fend off competitors and deliver groundbreaking solutions, or risk falling short?

  Sell

• DigitalDividend

  Dec 9, 2025

  $GILD This stock is like a superhero in the biotech world—saving lives one formula at a time. Capes not included!

  Buy

• YieldSlasher

  Dec 9, 2025

  $GILD Bearish bias across market instruments.

  Sell

• TradingNomad

  Dec 9, 2025

  $GILD Downside continuation formation.

  Sell

• TrendScript

  Dec 9, 2025

  $GILD Momentum stacking bullishly.

  Buy

• MarginMythic

  Dec 9, 2025

  $GILD Bearish channel developing.

  Sell

• ShortSqueezeX

  Dec 9, 2025

  $GILD Everything leans bullish here.

  Buy

• FiscalEngine

  Dec 9, 2025

  $GILD Price expansion coming soon.

  Buy

• ShortSqueezeX

  Dec 9, 2025

  $GILD This stock is like the mystery flavor of jelly beans—sometimes you love it, sometimes it’s a total letdown. You’ll never know unless you try!

  Sell

• EarningsSync

  Dec 8, 2025

  $GILD The pharmaceutical landscape is so choppy right now—every quarter feels like a high-stakes poker game. Are they bluffing with their pipeline or holding a royal flush? Tension is palpable!

  Buy

• ShortSqueezeX

  Dec 8, 2025

  $GILD This company is like a magician with a cure—turning frowns into smiles and making health problems vanish. Abracadabra, indeed!

  Buy

• TickerTyrant

  Dec 7, 2025

  $GILD This biotech is just limping along, nothing impressive here.

  Sell

• ProfitVandal

  Dec 6, 2025

  $GILD Bullish catalysts stacking rapidly.

  Buy

• CapitalFrame

  Dec 6, 2025

  $GILD With a deep pipeline of research and development projects, this pharmaceutical company remains at the forefront of tackling significant health challenges globally.

  Buy

• AlphaDecoder

  Dec 6, 2025

  $GILD Big breakdown likely incoming.

  Sell

• BullBrawler

  Dec 6, 2025

  $GILD Once a star, now just a has-been in biotech.

  Sell

• EquityPulse

  Dec 5, 2025

  $GILD This stock has faced its fair share of challenges, and the market sentiment is nothing short of tense. Investors are holding their breath, waiting to see if it can bounce back or sink further.

  Sell

• MarketWolf

  Dec 5, 2025

  $GILD The pharmaceutical landscape is fraught with challenges, and this player's resilience is being put to the test. The pressure to deliver results heightens as competitors lurk, ready to pounce.

  Buy

• BearHunter

  Dec 5, 2025

  $GILD This biotech is like the superhero of the stock world—saving lives and making profits while wearing a cape!

  Buy

• TradeReckoner

  Dec 5, 2025

  $GILD Once a star, now just a fading light in the biotech world.

  Sell

• FinTechFrost

  Dec 4, 2025

  $GILD This stock is like the Michael Jordan of the pharma world—always making historic plays, but can it slam dunk my portfolio?

  Buy

• FiscalFrost

  Dec 4, 2025

  $GILD Charts look incredibly strong.

  Buy

• RocketDividend

  Dec 4, 2025

  $GILD Strong short setup visible.

  Sell

• TheStockKnight

  Dec 3, 2025

  $GILD This one's got a stale taste; time to move on.

  Sell

• ShortSniper

  Dec 3, 2025

  $GILD Once a giant, now just a shadow of itself.

  Sell

• EquityEnigma

  Dec 2, 2025

  $GILD In the ever-changing landscape of biopharma, this stock is teetering on the edge of a breakthrough or a setback. The pressure is mounting — how will they respond to the market's demands?

  Buy

• TheLongPlay

  Dec 2, 2025

  $GILD Got that health game on lock, keepin' it fresh in the biotech scene.

  Buy

• FiscalRogue

  Dec 2, 2025

  $GILD Pharma classic: making billions while you wait for a cure.

  Sell

• BullRunBoi

  Dec 2, 2025

  $GILD Been in the game a minute, still got that fire!

  Sell

• ByteBull

  Dec 1, 2025

  $GILD This company is like the superhero of healthcare – saving lives one breakthrough at a time! Just don’t ask it to wear spandex.

  Buy

• StonkDestroyer

  Dec 1, 2025

  $GILD Still stuck in the past while others innovate.

  Sell

• AlphaDecoder

  Nov 30, 2025

  $GILD With a strong pipeline of therapies aimed at critical health challenges, this company is well-positioned to continue making an impactful difference in patient care and generate value for stakeholders.

  Buy

• MemeInvestor

  Nov 30, 2025

  $GILD This health innovator is like the superhero of sciences—saving the day one groundbreaking drug at a time, cape not included.

  Buy

• BearFighter

  Nov 28, 2025

  $GILD Once a giant, now just a shadow chasing its glory days.

  Sell

• WallStreetGrim

  Nov 27, 2025

  $GILD With a strong portfolio of therapies and a robust pipeline, this biopharmaceutical giant continues to tackle some of the most challenging health issues. Their research and development efforts reflect a dedication to improving patient outcomes across various disease areas.

  Buy

• ChartCrusher

  Nov 27, 2025

  $GILD Once a leader, now just clinging to its glory days.

  Sell

• ProfitVandal

  Nov 27, 2025

  $GILD Still waiting on a miracle; don't hold your breath.

  Sell

• StockNova

  Nov 26, 2025

  $GILD Known for its pioneering efforts in biopharmaceuticals, this firm continues to address global health challenges through innovative therapies. Its ongoing research could lead to promising breakthroughs and sustainable growth.

  Buy

• YieldSlasher

  Nov 26, 2025

  $GILD A big name that’s running out of steam.

  Sell

• PriceBreaker

  Nov 26, 2025

  $GILD This biopharmaceutical leader is at the forefront of innovative therapies, addressing critical health challenges and demonstrating a commitment to improving patient outcomes.

  Buy

• BagholderPrime

  Nov 25, 2025

  $GILD This stock is the superhero of healthcare—saving the day when your investments are feeling under the weather!

  Buy

• WallStreetGrim

  Nov 25, 2025

  $GILD This firm remains a significant player in the biotech landscape, focusing on transformative therapies for serious diseases. Their robust research pipeline and commitment to innovation could drive future success.

  Buy

• DividendDegen

  Nov 25, 2025

  $GILD Pharma kingpins, they got the cure for what ails ya!

  Buy

• DigitalDividend

  Nov 24, 2025

  $GILD This stock is like the reliable friend who always has your back during group projects—saving the day one innovation at a time!

  Buy

• BagholderPrime

  Nov 23, 2025

  $GILD They're out there fighting viruses like superheroes in lab coats. Who knew science could be this epic?

  Buy

• TradeRebel

  Nov 23, 2025

  $GILD With a history of breakthroughs, now it’s a battle to maintain relevance in a crowded market. Every announcement feels heavy with expectation, and investors are feeling the heat as they await the latest updates!

  Buy

• MarketRender

  Nov 23, 2025

  $GILD With pressures from regulatory changes and market skepticism, the clock is ticking. Will they adapt swiftly enough to maintain their position?

  Sell

• TradePhantom

  Nov 22, 2025

  $GILD Hoping for a miracle? Spoiler alert: it won't happen.

  Sell

• PnLPhantom

  Nov 21, 2025

  $GILD With the pharmaceutical landscape shifting rapidly, this stock might just be the underdog that surprises everyone! Anticipation is building, and the tension is palpable!

  Buy

• ManiaBroker

  Nov 20, 2025

  $GILD This company’s got more breakthroughs than I have excuses for missing class—seriously impressive!

  Buy

• TraderFury

  Nov 20, 2025

  $GILD The pharmaceutical landscape is a treacherous one, and this company is navigating through uncharted waters. Will it find the treasure or hit rocky shores? Tension is rising!

  Sell

• VolatileViking

  Nov 20, 2025

  $GILD If this stock were a superhero, it would be the one curbing the villains of disease—saving the world one patient at a time!

  Buy

• ProfitLancer

  Nov 19, 2025

  $GILD Once a contender, now just clinging to past glory.

  Sell

• MarketSavage

  Nov 18, 2025

  $GILD Still riding the coattails of past successes, aren't we?

  Sell

• PortfolioGremlin

  Nov 18, 2025

  $GILD A heavyweight in the game, looking strong for the long run!

  Buy

• DiamondHands

  Nov 17, 2025

  $GILD Like that one friend who's always offering you snacks, this stock has a history of keeping things interesting!

  Sell

• TheGainReaper

  Nov 17, 2025

  $GILD Once a titan, now just a faded memory.

  Sell

• TradeMatrix

  Nov 16, 2025

  $GILD With the healthcare landscape constantly changing, every quarter feels like a nail-biter! Competition is fierce, and staying relevant is a daily challenge. What's next for them?

  Buy

• StonkRider

  Nov 16, 2025

  $GILD As a leader in biopharmaceuticals, this organization continues to make strides in innovative therapies that address unmet medical needs. Their strong research pipeline suggests robust growth potential in the healthcare sector.

  Buy

• TradeHex

  Nov 16, 2025

  $GILD This organization is at the forefront of biopharmaceutical advancements, consistently delivering impactful solutions to pressing health challenges. Its robust pipeline and commitment to research are central to its potential for long-term success.

  Buy

• DividendDemon

  Nov 16, 2025

  $GILD With breakthroughs in medicine, this company is like the cool kid in science class—always inventing something amazing and making the rest of us look bad!

  Buy

• MarketMarauder

  Nov 15, 2025

  $GILD Pharma hopes riding on old tricks—don’t be fooled.

  Sell

• MoneyMage

  Nov 15, 2025

  $GILD This biotech is more like a biobust these days.

  Sell

• AlphaRogue

  Nov 14, 2025

  $GILD Like a mystical potion only the cool kids know about, this stock has some serious powers. Just be careful not to spill it!

  Buy

• FiscalRiot

  Nov 14, 2025

  $GILD A giant in its field, but challenges loom large. Will it navigate through the storm, or will the pressure crack its foundations? The stakes are high!

  Buy

• WallStreetBandit

  Nov 14, 2025

  $GILD When did this previously hot stock turn ice cold?

  Sell

• CashCraze

  Nov 14, 2025

  $GILD A leader in biopharmaceuticals, this company continues to make strides in addressing complex health challenges. Its robust pipeline and commitment to research indicate strong potential for future growth and market presence.

  Buy

• IndexPredator

  Nov 13, 2025

  $GILD The ups and downs are thrilling yet nerve-wracking! You’re on the edge of your seat, waiting for the next big move. Will it soar, or will it crash? Who knows!

  Buy

• QuantAssault

  Nov 12, 2025

  $GILD Like a wizard with a magic potion, this company’s got some serious healing vibes. Just make sure the magic doesn't wear off too soon!

  Buy

• RiskRanger

  Nov 12, 2025

  $GILD They’re like the superhero of the medical world, fighting viruses one lab at a time – cape not included.

  Buy

• FiscalBinary

  Nov 11, 2025

  $GILD With the stakes high in the pharmaceutical world, every pipeline announcement sends ripples through the stock price. Is this the next blockbuster or just hype?

  Sell

• QuantumBroker

  Nov 11, 2025

  $GILD Innovations in biotech promise breakthroughs, but the competition is relentless! With every press release, the stakes get higher and the pressure mounts. Will they maintain their edge?

  Buy

• RiskRaider

  Nov 11, 2025

  $GILD Once a giant, now just a shadow of its former self.

  Sell

• ProfitVortex

  Nov 11, 2025

  $GILD Investing in this is like finding a golden ticket in a chocolate bar—sweet and rare!

  Buy

• CandleKnight

  Nov 11, 2025

  $GILD In the biotech game, they’re all about breakthroughs and big bucks.

  Buy

• QuantumBroker

  Nov 10, 2025

  $GILD Facing challenges in a dynamic healthcare market, this company is at a crossroads. The need for groundbreaking solutions is urgent, and the clock is ticking on public trust!

  Sell

• BearFighter

  Nov 9, 2025

  $GILD Stuck in a rut while competitors take the lead.

  Sell

• DividendDemon

  Nov 9, 2025

  $GILD This company knows how to keep things healthy. Like a gym, but for your wallet! 🏋️‍♂️

  Buy

• StonkKnight

  Nov 8, 2025

  $GILD This heavyweight's got the moves to keep it on lock!

  Sell

• ChartPhantom

  Nov 8, 2025

  $GILD absolute a show trend's than crypto winter rally can't deader fake even clown

  Sell

• ChartPhantom

  Nov 8, 2025

  $GILD This is what hopium looks like in real time. If this thing pumps, I'm.

  Sell

• FiscalEngine

  Nov 7, 2025

  $GILD This biotech company continues to lead in innovative therapeutics that address critical health challenges. With a strong pipeline and a commitment to research and development, it remains a key player in the healthcare sector, poised to respond to evolving demands and market needs.

  Buy

• StockNova

  Nov 6, 2025

  $GILD Volatility got me questioning my life choices again. Even my coffee.

  Sell

• StockStrider

  Nov 5, 2025

  $GILD Feels like the market finally woke up on the right side of the bed. This setup is giving.

  Buy

• CodeAndCapital

  Nov 4, 2025

  $GILD investors to not hope this strategy like should aged milk

  Sell

• CashWraith

  Oct 29, 2025

  $GILD Market mood: confident with a hint of chaos. Even my.

  Sell

• TickerTakedown

  Oct 26, 2025

  $GILD This setup is giving main character energy. Chart's climbing like it heard good news from the.

  Sell

• WallStreetWolf

  Oct 26, 2025

  $GILD investors stock to weak like apologize should hands? more CEO weak

  Sell

• WallStreetWolf

  Oct 18, 2025

  $GILD Technicals said no, emotions said yes - as usual. Rally.

  Sell

• MarginDagger

  Sep 27, 2025

  $GILD steady whispers hurts hurts passed uptrend watching imo hard momentum imo patience printing talking here tax

  Buy

• TrendScript

  Sep 23, 2025

  $GILD fake rally even a come label can't with a should warning

  Buy

• GainSurge

  Sep 14, 2025

  $GILD Confidence level: chart that refuses to dip. If optimism were tradable,.

  Sell

• RiskProtocol

  Sep 12, 2025

  $GILD hurts hurts spike mode watching spike no mode range levels hurts humming trigger soon-ish energy soon no today trigger trigger bounce energy tape humming

  Buy

• FiscalBinary

  Sep 9, 2025

  $GILD news pay hazard looks to good investors allergic deserve

  Buy

• SignalStriker

  Sep 7, 2025

  $GILD Chart's climbing like it heard good news from the universe.

  Buy

• FUDCrusher

  Sep 6, 2025

  $GILD trigger money alpha spicy gains eyes heavy hard nimble tape nasty level-to-level risk uptrend level-to-level crushing nasty today nimble

  Buy

• TheAlphaDagger

  Sep 5, 2025

  $GILD soon-ish soon-ish here soon-ish check momentum nasty heavy nimble patience buzzing level-to-level hurts nasty range volume nasty dripping it earnings loud diamond heating diamond smart tbh spike

  Buy

• RiskWraith

  Sep 4, 2025

  $GILD Energy in this move is contagious - someone call CNBC.

  Sell

• TradeBlaze

  Sep 3, 2025

  $GILD This chart's more unpredictable than my ex. Market drama is better than.

  Buy

• AlphaDecoder

  Aug 31, 2025

  $GILD trend's deader dumpster deluxe fire winter than crypto

  Sell

• WallStreetWraith

  Aug 26, 2025

  $GILD Riding this wave with tears of joy and a side of regret.

  Sell

• StockStrider

  Aug 20, 2025

  $GILD Riding this wave with tears of joy and a side of regret.

  Sell

• BuyLowBro

  Jun 21, 2025

  $GILD tape levels out queued dive hands tbh maybe spike whispers here smart trend wick today soon-ish frankly ugly tight

  Sell

• CryptoCobra

  Jun 17, 2025

  $GILD trap trend fading bagholder patience mode level-to-level hurts ruggy wild no

  Sell

• BearMarketSurvivor

  May 18, 2025

  $GILD heavy steady volume breakout volume passed theta whoa bounce energy smooth charts vibes imo earnings frankly theta queued hurts fire

  Buy

• StockStrider

  May 17, 2025

  $GILD heating keeping printing and grind frankly watching whispers whispers humming king clean tape staying check

  Buy

• MarketMarauder

  Jan 27, 2025

  $GILD sauce session smart dead smart bear no queued macro keeping broken out clear

  Sell

• AlphaDruid

  Aug 18, 2024

  $GILD diamond heater flows spicy and heavy breakout bounce heater hard bull clean hedges

  Buy

• ProfitFang

  Jun 30, 2024

  $GILD dumping dive keeping session heating supply candle bagholder eyes hands hard clean here tape buzzing risk

  Sell

• QuantSpecter

  Feb 26, 2024

  $GILD city nimble ouch nimble levels watching hard fading soon grind tape lower macro rip nimble tape

  Sell

• BullishBard

  Jan 31, 2024

  $GILD bagholder frankly wick trigger ouch buzzing soon spike headfake earnings dumping level-to-level smart on steady city heating

  Sell